PFECL Stock Overview
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Pfizer Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$28,095.00 |
| 52 Week High | US$30,109.00 |
| 52 Week Low | US$22,838.00 |
| Beta | 0.61 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -32.51% |
| 33 Year Change | -27.28% |
| 5 Year Change | n/a |
| Change since IPO | -9.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| PFECL | CL Pharmaceuticals | CL Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | -32.5% | 0% | 0% |
Return vs Industry: PFECL underperformed the CL Pharmaceuticals industry which returned -18.8% over the past year.
Return vs Market: PFECL underperformed the CL Market which returned 10.5% over the past year.
Price Volatility
| PFECL volatility | |
|---|---|
| PFECL Average Weekly Movement | 0% |
| Pharmaceuticals Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in CL Market | 0% |
| 10% least volatile stocks in CL Market | 0% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine PFECL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1849 | 88,000 | Albert Bourla | www.pfizer.com |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands.
Pfizer Inc. Fundamentals Summary
| PFECL fundamental statistics | |
|---|---|
| Market cap | CL$138.71t |
| Earnings (TTM) | CL$4.16t |
| Revenue (TTM) | CL$57.83t |
33.3x
P/E Ratio2.4x
P/S RatioIs PFECL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PFECL income statement (TTM) | |
|---|---|
| Revenue | US$59.38b |
| Cost of Revenue | US$17.94b |
| Gross Profit | US$41.43b |
| Other Expenses | US$37.16b |
| Earnings | US$4.27b |
Last Reported Earnings
Sep 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.75 |
| Gross Margin | 69.78% |
| Net Profit Margin | 7.20% |
| Debt/Equity Ratio | 73.4% |
How did PFECL perform over the long term?
See historical performance and comparisonDividends
6.7%
Current Dividend Yield221%
Payout RatioDoes PFECL pay a reliable dividends?
See PFECL dividend history and benchmarks| Pfizer dividend dates | |
|---|---|
| Ex Dividend Date | Nov 08 2024 |
| Dividend Pay Date | Dec 02 2024 |
| Days until Ex dividend | 14 days |
| Days until Dividend pay date | 10 days |
Does PFECL pay a reliable dividends?
See PFECL dividend history and benchmarks